~~<i id='23CE30C9A0'><strike id='23CE30C9A0'><tt id='23CE30C9A0'><pre id='23CE30C9A0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：fashion 2025-08-12 06:41:58 - browse：657

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Supreme Court mifepristone arguments center on docs' right to sue

leisure time

focus

explore

knowledge

explore

AdobeTodayistheinauguralpublishingdayforAdam’sBiotechScorecard—asubscriber-onlynewsletterofferingsen

WSS

FDA warns medical device makers about rise in fabricated data

FDA warns medical device makers about rise in fabricated data

Vertex Pharmaceuticals may move headquarters in Boston

Elevance, SCAN deals highlight health insurer acquisition scrutiny

FDA warns medical device makers about rise in fabricated data

There's no autism epidemic. It's an autism diagnosis epidemic

focus

comprehensive

leisure time

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Decaf coffee targeted by food safety group under obscure FDA rule

BioMarin wins approval for gene therapy to treat hemophilia A

Oprah kicked off a national conversation on obesity. Let's have it

Jerome Adams on the need for new antivirals for Covid

Abortion pill Supreme Court ruling could impact entire drug industry

The high cost of giving birth even with insurance

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

Abortion pill Supreme Court ruling could impact entire drug industry

Measles policy set amid Florida outbreak alarms vaccine proponents

FDA's naming rule on biosimilars has undermined competition

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Ukraine seeks to reclaim its role as a hub for clinical trials

Readout Newsletter: Merck, Vertex, and Viking updates

focus

explore

knowledge

explore